Using clinical and diagnostic indices to assess the severity of pemphigus (a comparative analysis)

Cover Page

Abstract


The article discusses clinical indices suggested for the assessment of the severity of the course of autoimmune bullous dermatosis - pemphigus. These indices make it possible to assess the severity of the disease in view of the localization and prevalence of blisters and/or erosions and patient’s subjective sensations as well as efficacy of the therapy, and to compare the study results. In spite of the great number of indices suggested for the assessment of the severity of pemphigus, none of them are generally recognized. The following indices are currently considered as the best known and most convenient for application in clinical practice: Pemphigus Disease Area Index (PDAI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Vulgaris Activity Score (PVAS). A number of studies demonstrated mutual correlation among ABSIS, PDAI and PVAS. However, the group of patients under examination mainly comprised people suffering from light to moderate forms of pemphigus, which makes it difficult to interpret the results of comparative studies. It is expedient for leading dermatovenerologists to carry out clinical studies based on a large group of patients with pemphigus of different severity to elaborate a common tool to assess the severity of pemphigus in the Russian Federation to be recommended by the Russian Society of Dermatovenerologists.

About the authors

A. A. Kubanov

State Research Center ofDermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation; Russian Medical Academy of Postgraduate Studies, Ministry of Health of the Russian Federation

Author for correspondence.
Email: abtava@mail.ru

Russian Federation

T. V. Abramova

Russian Medical Academy of Postgraduate Studies, Ministry of Health of the Russian Federation

Email: noemail@neicon.ru

Russian Federation

References

  1. Кубанов А.А., знаменская Л.Ф., Абрамова Т.В., Свищенко С.И. К вопросам диагностики истинной акантолитической пузырчатки. Вестн дерматол венерол 2014; 6: 121-130
  2. Tamgadge S., Tamgadge A., Bhatt D.M., Bhalerao S., Pereira T. Pemphigus vulgaris. Contemp Clin Dent 2011; 2: 134-137
  3. Grando S.A. Pemphigus autoimmunity: Hypotheses and realities. Autoimmunity 2012; 45: 7-35
  4. Кубанова А.А., карамова А.Э., Кубанов А.А. Поиск мишеней для таргетной терапии аутоиммунных заболеваний в дерматологии. Вестн росс акад мед наук 2015; 70 (2): 159-164
  5. Кубанов А.А., Абрамова Т.В. Современные методы терапии истинной акантолитической пузырчатки. Вестн дерматол венерол 2014; 4: 19-27
  6. Martin L.K., Werth V., Villanueva E., Segall J., Murrell D.F. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; (1): CD006263
  7. Chams-Davatchi C., Rahbar Z., Daneshpazhooh M., Mortazavizadeh S.M., Akhyani M., Esmaili N., Balighi K. Pemphigus vulgaris activity score and ssessment of convergent validity. Acta Med Iran 2013; 51 (4): 224-230.
  8. Tjokrowidjaja A., Daniel B.S., Frew J.W. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. Br J Dermatol 2013 Nov; 169 (5): 1000-1006.
  9. Zhao C.Y., Murrell D.F. Outcome measures for autoimmune blistering diseases. J Dermatol 2015 Jan; 42 (1): 31-36.
  10. Hertl M., Jedlickova H., Karpati S., Marinovic B., Uzun S., Yayli S., Mimouni D., Borradori L., Feliciani C., Loannides D., Joly P., Kowalewski C., Zambruno G., Zillikens D., Jonkman M.F. Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J. Eur. Acad Dermatol Venereol 2015; 29 (3): 405-414.
  11. Murrell D.F., Amagai M., Werth V.P. Scoring systems for blistering diseases in practice: why bother, and which one should you use? JAMA dermatology. American Medical Association 2014; 150 (3): 245-247.
  12. Wallace A.B. The exposure treatment of burns. Lancet. 1951; 1: 501-504.
  13. Livingston M.D., Edward H., Lee, B.S. Percentage of Burned Body Surface Area Determination in Obese and Nonobese Patients. J Surg Res 2000; 91 (2): 106-110.
  14. Kalra S. Assessment of burn area: Can we be more objective? Burns 2006; 32 (1): 134.
  15. Guzzo C.A., Weiss J.S., Mogavero H.S. et al. A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses. J Am Acad Dermatol 1991; 25 (6), Pt 2.: 1179-1183.
  16. Heald P., Mehlmauer M., Martin A.G., Crowley C.A., Yocum R.C., Reich S.D. Topical bexaro-tene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. Elsevier 2003; 49 (5): 801-815.
  17. Langley R.G., Ellis C.N. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004; 51 (4): 563-569.
  18. Hundley J.L., Carroll C.L., Lang W. et al. Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol 2006; 54 (2): 217-220.
  19. Rosenbach M., Murrell D.F., Bystryn J.C. et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009 (Oct); 129 (10): 2404-2410.
  20. Daniel B.S., Hertl M., Werth V.P. et al. Severity score indexes for blistering diseases. Clin Dermatol 2012; 30 (1): 108-113.
  21. Ikeda S., Immamara S., Hashimoto I., Morioka S., Sakuma M., Ogawa H. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan. Arch Dermatol Res 2003; 295, Suppl 1: 12-16.
  22. Benchikhi H., Nani S., Baybay H. et al. Pemphigus: use of the Japanese severity index in 56 Moroccan patients. Pan Afr Med J 2013; 16: 96.
  23. Agarwal M., Walia R., Kochhar A.M., Chander R. Pemphigus Area and Activity Score (PAAS)-a novel clinical scoring method for monitoring of pemphigus vulgaris patients. Int J Dermatol 1998; 37 (2): 158-160.
  24. Адаскевич В.П. количественная оценка степени тяжести дерматозов. Дерматология 2014; 2: 24-31
  25. Mortazavi H., Kiavash K., Esmaili N., Chams-Davatchi C. Correlation of pemphigus vulgaris antibody titers by indirect immunofluorescence with activity of disease based on Pemphigus Area and Activity Score (PAAS). Acta Medicum Iran 2008; 46 (3): 559-564.
  26. Pfütze M., Niedermeier A., Hertl M., Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J dermatology 2007; 17: 4-11.
  27. Grover S. Scoring systems in pemphigus. Indian J Dermatol 2011; 56: 145-149.
  28. Harman K.E., Seed P.T., Gratain M.J., Bhogal B.S., Challacombe S.J., Black M.M. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001; 144 (4): 775-780.
  29. Свирщевская Е.В., Матушевская Е.В., Дзуцева И.Р., Марченко А.Н., Лысенко А.А. Разработка иммуноферментной тест-системы на основе дрожжевого рекомбинантного десмоглеина 3 для серодиагностики вульгарной пузырчатки. Вестн дерматол венерол 2005; 3: 4-10
  30. Ishii K., Amagai M., Hall R.P. et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159(4): 2010-2017.
  31. Herrero-Gonzalez J.E., Iranzo P., Benitez D. et al. Correlation of immunological profile with phenotype and disease outcome in pemphigus. Acta Derm Venereol 2010; 90 (4): 401-405.
  32. Schmidt E., Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010; 10: 84-89.
  33. Дерматология Фицпатрика в клинической практике: в 3 т. Вольф К., Голдсмит Л.А., Кац С.И. и др. Пер. с англ.; общ. ред. акад. А.А. Кубановой. М: Изд-во Панфилова; БИНОМ. Лаборатория знаний 2012; 1; 550-511
  34. Saraswat A., Bhushan K., India C. A new grading system for oral pemphigus. Int J Dermatol 2003; 42 (5): 413-414
  35. Mahajan V.K., Sharma N.L., Sharma R.C., Garg G. Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases. Int J Dermatol 2005; 44 (10): 821-827
  36. Адаскевич В.П. Диагностические индексы в дерматологии. М: Изд-во Панфилова; БИНОМ. Лаборатория знаний 2014; 352
  37. Kumar B., Arora S., Kumaran M.S. et al. Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus // Ind J Dermatol Venereol Leprol Medknow Publications 2006; 72 (3): 203
  38. Kautz O., Hertl M., Sticherling M., Zillikens D., Bruckner-Tuderman L. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009; 7: 227-233
  39. Колос Ю.В., Лукьянов А.М. Использование клинических индексов для оценки степени тяжести течения пузырчатки. Медицинская панорама. Рецензируемый научно-практический журнал для врачей 2013; 1: 69-74
  40. Kamiya K., Aoyama Y., Shirafuji Y. et al. A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris. J Dermatol Sci 2013 (Jun); 70 (3): 190-195
  41. Patsatsi A., Kyriakou A., Giannakou A. et al. Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in Pemphigus Patients Measured by Area Index and Intensity Score. Acta Derm Venereol 2014; 94 (2): 203-206
  42. Rahbar Z., Daneshpazhooh M., Mirshams-Shahshahani M. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score. JAMA dermatology 2014; 150 (3): 266-272
  43. Адаскевич В.П. Диагностические индексы в дерматологии. М, Медицинская книга. 2004: 164

Statistics

Views

Abstract - 199

PDF (Russian) - 122

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies